Suplementasi kromium dan kendali glikemik pada diabetes melitus tipe 2: tinjauan kritis literatur
DOI: 10.30867/gikes.v7i3.3666Abstract
Background: Clinical findings on chromium supplementation in type 2 diabetes mellitus (T2DM) remain inconsistent, and benefits of combination products are not necessarily attributable to chromium.
Objectives: To critically compare recent glycemic evidence, distinguish chromium-specific from combination effects, and examine safety and methodological limitations.
Methods: A critical literature review involved targeted verification of publications from 2017–2026 using PubMed/PMC records, publisher websites, and authoritative diabetes information resources in October 2026. Primary T2DM interventions, observational evidence, and published syntheses were interpreted separately. The review did not claim an exhaustive systematic search, a new meta-analysis, or a formal assessment of risk of bias or certainty of evidence.
Results: Twenty-five references informed the review. A placebo-controlled trial reported improved insulin resistance without a significant fasting-glucose benefit; another trial reported a substantial within-group reduction in HbA1c. Multicomponent studies evaluated combinations or ingredients other than chromium. Published evidence syntheses reported average glycemic benefits, but an umbrella review rated chromium-related HbA1c evidence as very low certainty. Baseline chromium measurements and dose–response patterns did not establish validated criteria for patient selection. Long-term safety evidence remained limited. The references included six clinical intervention reports (two chromium-focused and four combination examples), three observational studies, four evidence syntheses, and 12 supporting sources; selection bias remains possible.
Conclusions: Recent evidence does not establish a consistent chromium-specific glycemic benefit or a standard supplementation regimen for T2DM. Findings support better-controlled research, rather than replacement of established nutrition and pharmacological care.Keywords
Full Text:
PDFReferences
Alkhalidi, F. (2023). A comparative study to assess the use of chromium in type 2 diabetes mellitus. Journal of Medicine and Life, 16(8), 1178–1182. https://doi.org/10.25122/jml-2023-0081
American Diabetes Association Professional Practice Committee for Diabetes. (2026a). 5. Facilitating positive health behaviors and well-being to improve health outcomes: Standards of care in diabetes—2026. Diabetes Care, 49(Suppl. 1), S89–S131. https://doi.org/10.2337/dc26-S005
American Diabetes Association Professional Practice Committee for Diabetes. (2026b). 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of care in diabetes—2026. Diabetes Care, 49(Suppl. 1), S132–S149. https://doi.org/10.2337/dc26-S006
Baethge, C., Goldbeck-Wood, S., & Mertens, S. (2019). SANRA—A scale for the quality assessment of narrative review articles. Research Integrity and Peer Review, 4, Article 5. https://doi.org/10.1186/s41073-019-0064-8
Chen, J., Kan, M., Ratnasekera, P., Deol, L. K., Thakkar, V., & Davison, K. M. (2022). Blood chromium levels and their association with cardiovascular diseases, diabetes, and depression: National Health and Nutrition Examination Survey (NHANES) 2015–2016. Nutrients, 14(13), Article 2687. https://doi.org/10.3390/nu14132687
Chen, S., Jin, X., Shan, Z., Li, S., Yin, J., Sun, T., Luo, C., Yang, W., Yao, P., Yu, K., Zhang, Y., Cheng, Q., Cheng, J., Bao, W., & Liu, L. (2017). Inverse association of plasma chromium levels with newly diagnosed type 2 diabetes: A case-control study. Nutrients, 9(3), Article 294. https://doi.org/10.3390/nu9030294
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B. (2022). Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 65(12), 1925–1966. https://doi.org/10.1007/s00125-022-05787-2
Derosa, G., Pascuzzo, M. D., D’Angelo, A., & Maffioli, P. (2019). Ascophyllum nodosum, Fucus vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 12, 1861–1865. https://doi.org/10.2147/DMSO.S212429
Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., Saslow, L., Uelmen, S., Urbanski, P. B., & Yancy, W. S., Jr. (2019). Nutrition therapy for adults with diabetes or prediabetes: A consensus report. Diabetes Care, 42(5), 731–754. https://doi.org/10.2337/dci19-0014
Fong, C., Alesi, S., Mousa, A., Moran, L. J., Deed, G., Grant, S., Tapia, K., & Ee, C. (2022). Efficacy and safety of nutrient supplements for glycaemic control and insulin resistance in type 2 diabetes: An umbrella review and hierarchical evidence synthesis. Nutrients, 14(11), Article 2295. https://doi.org/10.3390/nu14112295
GBD 2021 Diabetes Collaborators. (2023). Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet, 402(10397), 203–234. https://doi.org/10.1016/S0140-6736(23)01301-6
Georgaki, M.-N., Tsokkou, S., Keramas, A., Papamitsou, T., Karachrysafi, S., & Kazakis, N. (2024). Chromium supplementation and type 2 diabetes mellitus: An extensive systematic review. Environmental Geochemistry and Health, 46(12), Article 515. https://doi.org/10.1007/s10653-024-02297-5
Huang, H., Chen, G., Dong, Y., Zhu, Y., & Chen, H. (2018). Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: Results from a pooled analysis. Molecular Nutrition & Food Research, 62(1), Article 1700438. https://doi.org/10.1002/mnfr.201700438
International Diabetes Federation. (2025). IDF diabetes atlas (11th ed.). https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/
Mohamed, M., Zagury, R. L., Bhaskaran, K., Neutel, J., Mohd Yusof, B. N., Mooney, L., Yeo, L., Kirwan, B.-A., Aprikian, O., von Eynatten, M., & Johansen, O. E. (2023). A randomized, placebo-controlled crossover study to evaluate postprandial glucometabolic effects of mulberry leaf extract, vitamin D, chromium, and fiber in people with type 2 diabetes. Diabetes Therapy, 14(4), 749–766. https://doi.org/10.1007/s13300-023-01379-4
Nayyar, H., Bhatti, A., John, P., & Khan, G. (2026). Clinical correlation of serum zinc and chromium levels in patients with type 2 diabetes mellitus and complications in Pakistan: A retrospective study. PeerJ, 14, Article e20184. https://doi.org/10.7717/peerj.20184
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., . . . Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, Article n71. https://doi.org/10.1136/bmj.n71
Pingali, U., Nutalapati, C., & Illendulla, V. S. (2020). Evaluation of the effect of fish oil alone and in combination with a proprietary chromium complex on endothelial dysfunction, systemic inflammation and lipid profile in type 2 diabetes mellitus—A randomized, double-blind, placebo-controlled clinical study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 31–42. https://doi.org/10.2147/DMSO.S220046
Sartore, G., Ragazzi, E., Antonello, G., Cosma, C., & Lapolla, A. (2021). Effect of a new formulation of nutraceuticals as an add-on to metformin monotherapy for patients with type 2 diabetes and suboptimal glycemic control: A randomized controlled trial. Nutrients, 13(7), Article 2373. https://doi.org/10.3390/nu13072373
Schandelmaier, S., Briel, M., Varadhan, R., Schmid, C. H., Devasenapathy, N., Hayward, R. A., Gagnier, J., Borenstein, M., van der Heijden, G. J. M. G., Dahabreh, I. J., Sun, X., Sauerbrei, W., Walsh, M., Ioannidis, J. P. A., Thabane, L., & Guyatt, G. H. (2020). Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ, 192(32), E901–E906. https://doi.org/10.1503/cmaj.200077
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., & Henry, D. A. (2017). AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 358, Article j4008. https://doi.org/10.1136/bmj.j4008
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., Emberson, J. R., Hernán, M. A., Hopewell, S., Hróbjartsson, A., Junqueira, D. R., Jüni, P., Kirkham, J. J., Lasserson, T., Li, T., . . . Higgins, J. P. T. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 366, Article l4898. https://doi.org/10.1136/bmj.l4898
Talab, A. T., Abdollahzad, H., Nachvak, S. M., Pasdar, Y., Eghtesadi, S., Izadi, A., Aghdashi, M. A., Mohammad Hossseini Azar, M. R., Moradi, S., Mehaki, B., & Moradi, S. (2020). Effects of chromium picolinate supplementation on cardiometabolic biomarkers in patients with type 2 diabetes mellitus: A randomized clinical trial. Clinical Nutrition Research, 9(2), 97–106. https://doi.org/10.7762/cnr.2020.9.2.97
Vincent, J. B., & Lukaski, H. C. (2018). Chromium. Advances in Nutrition, 9(4), 505–506. https://doi.org/10.1093/advances/nmx021
Wan, S., He, J., Simoes, E. J., Mechanick, J. I., Wu, W.-C., An, P., & Liu, S. (2023). Chromium supplementation to reduce cardiometabolic risk factors: A novel dose-response meta-analysis of randomized clinical trials. JACC: Advances, 2(10), Article 100729. https://doi.org/10.1016/j.jacadv.2023.100729
Refbacks
- There are currently no refbacks.











